Akalux (cetuximab sarotalocan) / Rakuten Medical 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   45 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Akalux (cetuximab sarotalocan) / Rakuten Medical
NCT03769506 / 2018-002513-36: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Recruiting
3
275
Japan, US, RoW
ASP-1929 Photoimmunotherapy, Physician's Choice SOC
Rakuten Medical, Inc.
Head and Neck Cancer
09/24
12/24
NCT05265013: ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

Terminated
2
16
RoW
ASP-1929 Photoimmunotherapy
Rakuten Medical, Inc.
Head and Neck Cancer
11/23
03/24
NCT05182866: ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

Active, not recruiting
2
9
US
ASP-1929 Photoimmunotherapy
Rakuten Medical, Inc., Shimadzu Corporation, National Cancer Institute (NCI)
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
07/24
06/26
NCT04305795: An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Active, not recruiting
1/2
74
US
200 mg Pembrolizumab, 350 mg Cemiplimab, ASP-1929
Rakuten Medical, Inc.
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
06/24
06/25

Download Options